ClinicalTrials.gg
Status unknownNCT03732508Updated Nov 6, 2018

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

A Phase 2 interventional study of Irinotecan liposome and SHR-1316 in Advanced Esophageal Squamous Cell Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-06.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Neoplasms, Squamous Cell with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Neoplasms, Squamous Cell · China.

Planned enrollment
10th of 15
30 · median 50
Started
2018
with 2 others
Phase 2
7 of 15
3 open now
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Jiangsu HengRui Medicine Co., Ltd.

Among the 15 studies in Neoplasms, Squamous Cell with a site in China, this one is the 10th largest by planned enrollment, is one of 3 that started in 2018, is one of 7 in phase 2, and was the 2nd registered.

Neoplasms, Squamous Cell

111 studies on the registry are indexed under Neoplasms, Squamous Cell; 19 are open to participants now.

Browse Neoplasms, Squamous Cell studies →

Open to participants now

5 of the 15 studies in Neoplasms, Squamous Cell with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Neoplasms, Squamous Cell studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neoplasms, Squamous Cell with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.

03

Conditions studied

  • Advanced Esophageal Squamous Cell Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed unresectable local advanced/recurrent or esophageal squamous cell carcinoma;
  2. No previous systemic anti-tumor treatment;
  3. Subjects must have at least one measurable tumor lesion per 1.1;
  4. : 0-1;
  5. Adequate organ and bone marrow function;

Exclusion criteria

Exclusion Criteria:

  1. Allergic to monoclonal antibodies, any SHR-1316 components,Irinotecan , Fluorouracil ;
  2. Prior therapy as follow:

    1. Anti- or anti-PD-L1;
    2. Any experimental drugs within 4 weeks of the first dose of study medication;
    3. Received major operations or serious injuries within 4 weeks of the first dose of study medication;
    4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;
  3. Not recovered to ≤ 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;
  4. Subjects with any active disease or history of autoimmune disease;
  5. Pregnancy or breast feeding;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Irinotecan liposome plus SHR1316 plus fluorouracil

    Drug: Irinotecan liposome · Drug: SHR-1316 · Drug: Fluorouracil

Interventions

  • Irinotecan liposome intravenous infusion will be administered during the first day of treatment.

  • SHR-1316 intravenous infusion will be administered during the first day of treatment.

  • Fluorouracil intravenous infusion will be administered during the first day of treatment.

06

What researchers measure

Primary outcomes

  1. Duration of Progression-Free Survival (PFS)

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

Secondary outcomes

  1. Disease Control Rate(DCR)

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  2. Objective Response Rate(ORR)

    based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)

    Time frame: approximately 22 months

  3. Overall Survival(OS)

    OS is defined as the time from registration to death due to any cause, or censored at date last known alive.

    Time frame: approximately 22 months

  4. Adverse Events(AE)

    adverse events

    Time frame: approximately 22 months

07

Study locations

1 of 1 sites recruiting
  • Cancer Institute and Hospital,Chinese Academy of Medical Science
    Beijing, Beijing 100000, China
    Recruiting
    • Jing Huang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2018; primary completion for Nov 2019, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 6, 2018
StartEst.
Nov 2018
Primary completionEst.
Nov 2019
CompletionEst.
Oct 2020
Last update
Nov 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03732508
Responsible party
Sponsor
First posted
Nov 6, 2018
Start date
Nov 2018 (estimated)
Primary completion
Nov 2019 (estimated)
Completion
Oct 2020 (estimated)
Last update
Nov 6, 2018

Study contacts

Fei Shi
Contact
hrshifei@163.com
+86-18036618733
Jing Huang
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion